PRHB Pure H2O Bio Technologies Inc New (CE)

Pure H2O Bio-Technologies, Inc. (Pink Sheets:PRHB) May 4, 2009 announced today the limitations over existing microbial removal and disinfection technologies.

PURE H20 BIO-TECHNOLOGIES, INC. Stock Symbol: PRHB Pink

Visit New Pilot Program For Integrated Hospital Potable Water Disinfection System Model 7000 www.pureh20biotech.com.

There are primarily two categories of technology that address the control of microbial contaminants such as Crytosporidium oocysts in drinking water. These include (1) physical removal and (2) inactivation or disinfection of disease causing agents such as Crytosporidium parvum.

Physical Removal of Microbial Etiological Agents

Ion-exchange carbon blocks and membrane in bag filters or cartridge filters are limited to removal based on pore size and may become compromised by particulate matter including the accumulation of biological material. In addition, these systems do not appear to address the different sizes (2�6 ?m) of Cryptosporidium during this parasite�s life-cycle which has several developmental stages: (i) motile zoite or merozoite, set free from ruptured schizonts; (ii) schizont, containing 8 merozoites when mature; (iii) mature merozoite; (iv) macrogametocyte. Filters with a 1 ?m nominal pore size may have a range of pore sizes from submicron to 30 ?m in diameter. Cryptosporidium cysts exhibit a certain cellular plasticity which enables them to pass through a 2 ?m pore (Crytosporidium from Molecules to Disease, pg. 298, 2003).

The common carbon-blocks systems sold for residential use typically have a functional life on the order of 2-3 months and are limited to treatment volumes of 40-100 gallons per filter.

Replacement costs of cartridge filters must be considered particularly in upscale applications. Overall, attempts at physical removal of oocysts fail to address the need to inactivate Cryptosproridium in drinking water.

Inactivation of Microbial Etiological Agents

The chlorine-resistance of Cryptosporidium is well documented in the scientific literature and is the basis for renewed interest in the control of this microbial parasite. Alternative methods of disinfection include ozone and UV-light treatment technologies.

Ozone, even when combined with chlorine post-treatment, may not inactivate all of the Cryptosoridium oocysts. Moreover, ozone dissipates quickly and its activity is limited by factors such as pH, turbidity, temperature, concentration, and carbon concentration. From a commercial or upscale perspective, ozonation is usually more expensive than chlorination and it can produce other undesirable chemical byproducts such as aldehydes, ketones, and carboxylic acids (Ozone in Water Treatment, pg. 265, 1991 and National Drinking Water Clearing house, Tech Brief, 1999).

UV-light water treatment is also limited by turbidity and may require substantial prefiltration. In addition, the intensity of the light may vary over time as the electrical elements undergo wear during repeated use. Moreover, this technology does not form a stable treatment residual and this can impact the effectiveness of the system. UV disinfection is considered to be even more expensive than ozonation.

New Technology Needed

Based on the limitations of existing water treatment technologies, there appears to be a need for more effective disinfection technology with application towards refractory water-borne parasites.

SOLUTION: Pure H20 Bio-Technologies, Inc. proprietary Silver TTOTM technology has the potential to disrupt the existing water treatment market in commercial, institutional as well as residential market sectors. SilverTetrasilverTetraoxide (SilverTTOTM) Water Disinfection of Resistant Cryptosporidium can be viewed on the Company�s web-sit: www.pureh20biotech.com.

See: PRHB Hospital Potable Water Disinfection System Model 7000, Pilot Program, Informational Video, Question & Answers Special Report T.V., Participant Revenue Sharing Agreement, Description of Hospital Model 7000.

� E-mail us with your comments or contact WesCom Capital, Inc. 1239 Water Street, Suite A, Port Townsend, Washington 98368 Telephone: 206.420.5710 Fax: 206.202.0760

Attention: Gary Schmidt E-mail: gls@wescomcapital.com

�

About Pure H2O Bio-Technologies, Inc.: Pure H2O Bio-Technologies, Inc. (PRHB) is a publicly held company specializing in the manufacturing, design, and sale of its unique residential, commercial and hospital point-of-use potable water disinfection systems. These systems are specifically designed to work effectively against water-borne pathogens and remove heavy metals and objectionable biomasses. PRHB has completed its engineering design and verified in laboratory bench, kinetic and pre-certification level studies with its state-of-the-art patent-pending treatment/delivery system. The Model 7000 system is also designed to remove chemical contaminants and metals that are present in source water. Certification of this system through EPA's contractor, National Sanitation Foundation (NSF) is underway. Upon completion of the Pilot Program Model 7000 will be available to hospitals and related medical facilities as a system delivering "pathogen-free and chemical-free" water. On July 31, 2007, the Company was awarded patent #7250111, and two additional patents pending at this time that are under review with the U.S. Patent and Trademark Office, Washington, D.C.

The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential," "suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development, and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.